Related Experiment Video
Updated: May 4, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.7K
Oral Hypoglycemic Agents in pregnancy: An Update
Nagandla Kavitha1, Somsubhra De1, Sachchithanantham Kanagasabai1
1Department of Obstetrics and Gynecology, Melaka Manipal Medical College, Jalan Batu Hampar, 75150 Bukit Baru, Melaka Malaysia.
Journal of Obstetrics and Gynaecology of India
|January 17, 2014
Summary
Oral hypoglycemic agents like glyburide and metformin are safe alternatives to insulin for managing diabetes in pregnancy. They show no increased risk of neonatal hypoglycemia or congenital anomalies.
Area of Science:
- Obstetrics and Gynecology
- Endocrinology
- Pharmacology
Background:
- Insulin is the traditional treatment for diabetes in pregnancy.
- Insulin therapy presents challenges including injections, cost, and storage.
- Oral hypoglycemic agents are being explored as alternatives.
Purpose of the Study:
- To review and evaluate the efficacy and safety of oral hypoglycemic agents.
- To assess current recommendations for their use in pregnancy.
Main Methods:
- Systematic review of existing evidence.
- Evaluation of clinical trial data.
- Analysis of safety and efficacy profiles.
Main Results:
- Glyburide and metformin show efficacy in managing Type 2 and gestational diabetes.
- No increased risk of neonatal hypoglycemia or congenital anomalies observed.
- Safety is currently limited to the prenatal period.
Conclusions:
- Glyburide and metformin are viable options for diabetes in pregnancy.
- Further research is needed on long-term neonatal and cognitive outcomes.
- Randomized controlled trials are recommended for long-term follow-up.
Related Concept Videos
01:06Oral Hypoglycemic Agents: Glinides
1.0K
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
953
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
953
01:26Hypoglycemia
30
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
30
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
993
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
993
01:15Hypoglycemia and Glucagon
1.3K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K
01:17Oral Hypoglycemic Agents: Sulfonylureas
1.7K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.7K